SG11201806567WA - Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites - Google Patents

Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites

Info

Publication number
SG11201806567WA
SG11201806567WA SG11201806567WA SG11201806567WA SG11201806567WA SG 11201806567W A SG11201806567W A SG 11201806567WA SG 11201806567W A SG11201806567W A SG 11201806567WA SG 11201806567W A SG11201806567W A SG 11201806567WA SG 11201806567W A SG11201806567W A SG 11201806567WA
Authority
SG
Singapore
Prior art keywords
international
cleavage sites
pct
san diego
compositions
Prior art date
Application number
SG11201806567WA
Other languages
English (en)
Inventor
Chun; Luo
Original Assignee
Cg Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cg Discovery Inc filed Critical Cg Discovery Inc
Priority claimed from PCT/US2017/016251 external-priority patent/WO2017136575A1/en
Publication of SG11201806567WA publication Critical patent/SG11201806567WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03H—IMPEDANCE NETWORKS, e.g. RESONANT CIRCUITS; RESONATORS
    • H03H7/00—Multiple-port networks comprising only passive electrical elements as network components
    • H03H7/01—Frequency selective two-port networks
    • H03H7/0115—Frequency selective two-port networks comprising only inductors and capacitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F1/00—Details of amplifiers with only discharge tubes, only semiconductor devices or only unspecified devices as amplifying elements
    • H03F1/02—Modifications of amplifiers to raise the efficiency, e.g. gliding Class A stages, use of an auxiliary oscillation
    • H03F1/0205—Modifications of amplifiers to raise the efficiency, e.g. gliding Class A stages, use of an auxiliary oscillation in transistor amplifiers
    • H03F1/0211—Modifications of amplifiers to raise the efficiency, e.g. gliding Class A stages, use of an auxiliary oscillation in transistor amplifiers with control of the supply voltage or current
    • H03F1/0216—Continuous control
    • H03F1/0222—Continuous control by using a signal derived from the input signal
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F1/00—Details of amplifiers with only discharge tubes, only semiconductor devices or only unspecified devices as amplifying elements
    • H03F1/56—Modifications of input or output impedances, not otherwise provided for
    • H03F1/565—Modifications of input or output impedances, not otherwise provided for using inductive elements
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F3/00—Amplifiers with only discharge tubes or only semiconductor devices as amplifying elements
    • H03F3/189—High-frequency amplifiers, e.g. radio frequency amplifiers
    • H03F3/19—High-frequency amplifiers, e.g. radio frequency amplifiers with semiconductor devices only
    • H03F3/193—High-frequency amplifiers, e.g. radio frequency amplifiers with semiconductor devices only with field-effect devices
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F3/00—Amplifiers with only discharge tubes or only semiconductor devices as amplifying elements
    • H03F3/189—High-frequency amplifiers, e.g. radio frequency amplifiers
    • H03F3/19—High-frequency amplifiers, e.g. radio frequency amplifiers with semiconductor devices only
    • H03F3/195—High-frequency amplifiers, e.g. radio frequency amplifiers with semiconductor devices only in integrated circuits
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B1/00—Details of transmission systems, not covered by a single one of groups H04B3/00 - H04B13/00; Details of transmission systems not characterised by the medium used for transmission
    • H04B1/005—Details of transmission systems, not covered by a single one of groups H04B3/00 - H04B13/00; Details of transmission systems not characterised by the medium used for transmission adapting radio receivers, transmitters andtransceivers for operation on two or more bands, i.e. frequency ranges
    • H04B1/0064—Details of transmission systems, not covered by a single one of groups H04B3/00 - H04B13/00; Details of transmission systems not characterised by the medium used for transmission adapting radio receivers, transmitters andtransceivers for operation on two or more bands, i.e. frequency ranges with separate antennas for the more than one band
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10W—GENERIC PACKAGES, INTERCONNECTIONS, CONNECTORS OR OTHER CONSTRUCTIONAL DETAILS OF DEVICES COVERED BY CLASS H10
    • H10W20/00—Interconnections in chips, wafers or substrates
    • H10W20/40—Interconnections external to wafers or substrates, e.g. back-end-of-line [BEOL] metallisations or vias connecting to gate electrodes
    • H10W20/495—Capacitive arrangements or effects of, or between wiring layers
    • H10W20/496—Capacitor integral with wiring layers
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10W—GENERIC PACKAGES, INTERCONNECTIONS, CONNECTORS OR OTHER CONSTRUCTIONAL DETAILS OF DEVICES COVERED BY CLASS H10
    • H10W20/00—Interconnections in chips, wafers or substrates
    • H10W20/40—Interconnections external to wafers or substrates, e.g. back-end-of-line [BEOL] metallisations or vias connecting to gate electrodes
    • H10W20/497—Inductive arrangements or effects of, or between, wiring layers
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10W—GENERIC PACKAGES, INTERCONNECTIONS, CONNECTORS OR OTHER CONSTRUCTIONAL DETAILS OF DEVICES COVERED BY CLASS H10
    • H10W44/00—Electrical arrangements for controlling or matching impedance
    • H10W44/20—Electrical arrangements for controlling or matching impedance at high-frequency [HF] or radio frequency [RF]
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10W—GENERIC PACKAGES, INTERCONNECTIONS, CONNECTORS OR OTHER CONSTRUCTIONAL DETAILS OF DEVICES COVERED BY CLASS H10
    • H10W72/00—Interconnections or connectors in packages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F2200/00—Indexing scheme relating to amplifiers
    • H03F2200/294—Indexing scheme relating to amplifiers the amplifier being a low noise amplifier [LNA]
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F2200/00—Indexing scheme relating to amplifiers
    • H03F2200/408—Indexing scheme relating to amplifiers the output amplifying stage of an amplifier comprising three power stages
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F2200/00—Indexing scheme relating to amplifiers
    • H03F2200/451—Indexing scheme relating to amplifiers the amplifier being a radio frequency amplifier

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Power Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
SG11201806567WA 2016-02-03 2017-02-02 Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites SG11201806567WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662290894P 2016-02-03 2016-02-03
PCT/US2017/016251 WO2017136575A1 (en) 2016-02-03 2017-02-02 Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites

Publications (1)

Publication Number Publication Date
SG11201806567WA true SG11201806567WA (en) 2018-08-30

Family

ID=63036971

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201806567WA SG11201806567WA (en) 2016-02-03 2017-02-02 Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
SG10202108573TA SG10202108573TA (en) 2016-02-03 2017-02-02 Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202108573TA SG10202108573TA (en) 2016-02-03 2017-02-02 Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites

Country Status (10)

Country Link
US (3) US10291197B2 (https=)
EP (1) EP3411712B1 (https=)
JP (2) JP7560938B2 (https=)
KR (1) KR102748840B1 (https=)
CN (2) CN114634916B (https=)
AU (2) AU2017215345B2 (https=)
CA (1) CA3012703A1 (https=)
MX (2) MX380837B (https=)
RU (2) RU2022108149A (https=)
SG (2) SG11201806567WA (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102465833B1 (ko) 2017-11-28 2022-11-11 삼성전자주식회사 무선 통신 시스템에서 전력 설정 방법 및 이를 위한 장치
KR102370100B1 (ko) * 2019-02-15 2022-03-07 아이디바이오 주식회사 이종 인플루엔자 a 바이러스에 대한 면역/치료반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 유전자 전달체 및 치료백신
CN117534737B (zh) * 2022-07-15 2024-09-06 中山大学·深圳 一种季节性甲型流感通用Mosaic重组抗原及其疫苗和应用
CN116874607B (zh) * 2023-06-09 2024-12-10 山西高等创新研究院 一种h9亚型禽流感重组嵌合疫苗及其制备方法
CN118978590B (zh) * 2024-10-12 2025-01-21 北京溯本源和生物科技有限公司 一种利用重组流感病毒免疫小鼠制备杂交瘤单抗的方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084180A1 (en) * 1991-12-11 1993-06-12 Paul P. Hung Expression of specific immunogens using viral antigens
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
DE10248301A1 (de) * 2002-10-16 2004-04-29 Philipps-Universität Marburg Herstellung eines Lebend-Impfstoffes gegen Influenza-Viren
DE10249294A1 (de) * 2002-10-22 2004-05-13 Rohmax Additives Gmbh Stabile Polymerdispersionen und Verfahren zur Herstellung
EA017887B1 (ru) * 2007-08-02 2013-03-29 Байондвакс Фармасьютикалз Лтд. Полимерные мультиэпитопные вакцины против гриппа
US20110177117A1 (en) 2008-07-18 2011-07-21 Normand Blais Chimeric respiratory syncytial virus polypeptide antigens
NZ590351A (en) 2008-07-18 2012-11-30 Medicago Inc HA1 domain totally or partially free of N-linked glycosylation operatively linked to a regulatory region
HUE039100T2 (hu) * 2009-06-24 2018-12-28 Medicago Inc Hemagglutinint tartalmazó kimer influenzavírus-jellegû részecskék
CN101857872A (zh) * 2010-04-06 2010-10-13 浙江省医学科学院 甲型流感病毒抗原决定区更换方法
WO2012114323A1 (en) * 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
EP4241785B1 (en) * 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
ES2832733T3 (es) * 2013-08-03 2021-06-11 Calder Biosciences Inc Métodos de preparación y uso de complejos de hemaglutinina del virus de la gripe
WO2016205347A1 (en) * 2015-06-16 2016-12-22 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof

Also Published As

Publication number Publication date
AU2024200382A1 (en) 2024-03-07
US11206005B2 (en) 2021-12-21
JP2023024998A (ja) 2023-02-21
US10291197B2 (en) 2019-05-14
CN114634916A (zh) 2022-06-17
CN109073639A (zh) 2018-12-21
CN114634916B (zh) 2024-12-20
RU2018131243A (ru) 2020-03-03
KR20180115717A (ko) 2018-10-23
JP2019506168A (ja) 2019-03-07
US20220200559A1 (en) 2022-06-23
RU2018131243A3 (https=) 2020-11-13
AU2024200382B2 (en) 2026-02-05
JP7560938B2 (ja) 2024-10-03
EP3411712A4 (en) 2019-12-04
RU2769406C2 (ru) 2022-03-31
AU2017215345B2 (en) 2023-10-19
BR112018015765A2 (pt) 2019-02-05
US20180334479A1 (en) 2018-11-22
KR102748840B1 (ko) 2025-01-02
CA3012703A1 (en) 2017-08-10
CN109073639B (zh) 2022-04-01
US11979133B2 (en) 2024-05-07
AU2017215345A1 (en) 2018-08-16
JP7577101B2 (ja) 2024-11-01
EP3411712B1 (en) 2025-11-19
MX380837B (es) 2025-03-12
MX2018009395A (es) 2018-11-09
US20190341901A1 (en) 2019-11-07
EP3411712C0 (en) 2025-11-19
MX2021003392A (es) 2021-05-27
EP3411712A1 (en) 2018-12-12
SG10202108573TA (en) 2021-09-29
RU2022108149A (ru) 2022-05-05

Similar Documents

Publication Publication Date Title
SG11201908280SA (en) "chimeric molecules and uses thereof"
SG11201909949XA (en) Targeted immunotolerance
SG11201810048VA (en) Tri-segmented pichinde viruses as vaccine vectors
SG11201808422QA (en) Gene therapy for treating hemophilia a
SG11201907714UA (en) Adeno-associated virus (aav) clade f vector and uses therefor
SG11201811432WA (en) Rna for cancer therapy
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201909322VA (en) Treatment of asthma with anti-tslp antibody
SG11201810522UA (en) Anti-cd40 antibodies and their uses
SG11201909868YA (en) Compositions and methods of treating huntington's disease
SG11201805229YA (en) Means and methods for treating hbv
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201907298WA (en) Methods and compositions for gene transfer across the vasculature
SG11201806567WA (en) Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
SG11201808751SA (en) T cell receptors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201805204WA (en) Nicotine particle capsule
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201906392WA (en) Nucleoside-modified rna for inducing an immune response against zika virus
SG11201901221YA (en) Methods for detecting aav
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201806639VA (en) New streptococcal proteases